AEGiS-ATN: Fomivirsen Approved for CMV Retinitis: First Antisense Drug

Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.

Fomivirsen Approved for CMV Retinitis: First Antisense Drug

AIDS TREATMENT NEWS Issue #302, September 4, 1998
John S. James

On August 27 the U.S. Food and Drug Administration approved the first drug using antisense technologyïfomivirsen (Vitravene(TM)) for patients "who are intolerant of or have a contraindication to other treatments for CMV retinitis or who were insufficiently responsive to previous treatments for CMV retinitis." This drug is injected directly into the eye, and is given monthly, except that the first two doses are two weeks apart. The drug was developed by Isis Pharmaceuticals, in cooperation with CIBA Vision, a unit of Novartis AG.

Antisense drugs work by blocking a specific gene from producing the protein it codes for. This kind of drug has great potential importance because it can be targeted against only a single geneïeither in a virus or other disease-causing organism, or an abnormal human gene. This highly specific action should improve efficacy and reduce side effects. The development of antisense drugs has been slower than some had expected, however, because of technological difficulties such as designing compounds which can readily enter cells.

Fomivirsen was considered on July 22 by an FDA advisory committee (the Ophthalmic Drugs Subcommittee of the Dermatologic and Ophthalmic Drugs Advisory Committee). The subcommittee voted 5-2 for approval, with all the clinicians voting to approve the drug; but there was much concern about the small number of patients in the trials, especially the pivotal study for "first line" use, which compared 18 patients randomly assigned to immediate treatment vs. 10 assigned to deferred treatment. The reason for these small numbers is that the availability of protease inhibitors greatly reduced the incidence of new CMV retinitis, making it very difficult to enroll volunteers into the trial. This small number of patients is probably the reason that the FDA did not grant the additional "first line" approval (for patients previously untreated for CMV retinitis) that the company had requested. There were more volunteers in the studies of fomivirsen for patients who had failed previous treatment for CMV retinitis.

An application to market fomivirsen in Europe is currently being reviewed.

Some information is available at http://www.fomivirsen.com and at http://www.cibavision.com. Also, the transcript of the FDA advisory committee hearing (on 7/22/98) will probably be placed on http://www.fda.gov, but it is not there as this article goes to press.

980904
ATN30206

Copyright © 1998 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org http://www.aidsnews.org

Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .